Our novel approach using CD4-directed therapy for AML is an alternative way to target an antigen that is not ubiquitously expressed on hematopoietic stem cell or non-hematopoietic cells, therefore circumventing potential relevant toxicities. This evidence concerns the gene CD4 and acute myeloid leukemia.